Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more

Location: 1 Enterprise Drive, Shelton, CT, 06484-4779, United States | Website: https://www.intensitytherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

11.12M

52 Wk Range

$0.18 - $4.19

Previous Close

$0.24

Open

$0.24

Volume

1,916,768

Day Range

$0.23 - $0.25

Enterprise Value

8.836M

Cash

2.216M

Avg Qtr Burn

-2.771M

Insider Ownership

12.71%

Institutional Own.

6.59%

Qtr Updated

06/30/25